« Previous
Next »
Titles
- OHRP generally conducted its compliance activities independently, but changes would strengthen its independence1
- OHRP should inform potential complainants of how they can seek whistleblower protections: 1
- Obesity in America: a growing threat1
- Older adult housing: future collaborations on housing and health services should include relevant agencies and define outcomes : report to the Ranking Member, Committee on Financial Services, House of Representatives1
- Older workers: Opioid misuse and employment outcomes : report to congressional requesters1
- Oncology drug products used with certain in vitro diagnostic tests: pilot program : guidance for industry, clinical laboratories, and Food and Drug Administration staff1
- Oncology pharmaceuticals: reproductive toxicity testing and labeling recommendations1
- Oncology therapeutic radiopharmaceuticals: nonclinical studies and labeling recommendations1
- One percent of drugs with Medicaid reimbursement were not FDA-approved1
- One quarter of Medicaid enrollees with HIV may not have received critical services in 20211
- Onsite surveys of nursing homes during the COVID-19 pandemic: March 23–May 30, 20201
- Opioid overdoses and the limited treatment of opioid use disorder continue to be concerns for Medicare beneficiaries1
- Opioid use decreased in Medicare Part D, while medication-assisted treatment increased1
- Opioid use disorder: barriers to Medicaid beneficiaries' access to treatment medications : report to Congressional committees1
- Opioid use disorder: developing depot buprenorphine products for treatment1
- Opioid use disorder: endpoints for demonstrating effectiveness of drugs for treatment1
- Opioid use disorder: opportunities to improve assessments of State Opioid Response grant program : report to congressional requesters1
- Opioid use disorder: treatment with injectable and implantable buprenorphine : report to Congressional committees1
- Opioid use disorders: HHS needs measures to assess the effectiveness of efforts to expand access to medication-assisted treatment : report to majority leader, U.S. Senate1
- Opioid use in Medicare Part D continued to decline in 2019, but vigilance is needed as COVID-19 raises new concerns1